Key result
Theophylline enhances biventricular systolic function and lowers PAP and PVR in patients with COPD.
Why the study?
Does theophylline improve cardiovascular performance in patients with chronic obstructive pulmonary disease?
Does theophylline improve cardiovascular performance in patients with chronic obstructive pulmonary disease?
Theophylline may have favorable cardiovascular effects in COPD patients beyond its bronchodilator properties by improving biventricular systolic function and lowering pulmonary vascular resistance.
Theophylline has been utilized widely as a bronchodilator. However, recent studies have shown the potential for administering this drug to enhance cardiovascular performance in patients with chronic obstructive pulmonary disease (COPD). Administered to COPD patients orally as a sustained-action preparation or intravenously as aminophylline, theophylline enhances both right and left heart systolic pump function and lowers both pulmonary artery pressure and pulmonary vascular resistance. These favorable cardiovascular actions suggest an additional use for theophylline in COPD beyond its effects as a bronchodilator.
No takes yet. Share an insight, caveat, or question.
Richard A. Matthay (1987) conducted a review in Chronic obstructive pulmonary disease (COPD). Theophylline was evaluated on Cardiovascular performance (right and left heart systolic pump function, pulmonary artery pressure, and pulmonary vascular resistance). Theophylline administration in patients with COPD enhances right and left heart systolic pump function and lowers pulmonary artery pressure and pulmonary vascular resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: